|
Volumn 158, Issue 12, 2001, Pages 2080-2082
|
Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low
a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE;
PINDOLOL;
SEROTONIN 1A RECEPTOR;
SEROTONIN UPTAKE INHIBITOR;
VENLAFAXINE;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
CONTROLLED STUDY;
DEPRESSION;
DRUG EFFICACY;
DRUG POTENTIATION;
DRUG RECEPTOR BINDING;
FEMALE;
HUMAN;
MALE;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ADULT;
BRAIN;
DEPRESSIVE DISORDER, MAJOR;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
PINDOLOL;
RECEPTORS, SEROTONIN;
RECEPTORS, SEROTONIN, 5-HT1;
SEROTONIN UPTAKE INHIBITORS;
TOMOGRAPHY, EMISSION-COMPUTED;
TREATMENT OUTCOME;
|
EID: 0035191933
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ajp.158.12.2080 Document Type: Article |
Times cited : (72)
|
References (10)
|